Please login to the form below

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NICE backs Bayer's Eylea in diabetic eye condition

The guidance will give Eylea a boost at a time when Bayer is looking to close the gap between its drug and Lucentis - and will give it a fillip after

Novartis launches Apple Watch app for the visually impaired

development. Novartis' eye-care interests centre around its Alcon division and its Wet AMD treatment Lucentis (ranibizumab) and its efforts to go 'beyond the pill' and develop additional digital health services

NICE no for new eye disease drug

drugs on the market, including Novartis/Roche's Lucentis (ranibizumab) and Bayer/Regeneron's Eylea (aflibercept).

Eylea growth closes the gap with Lucentis

Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... Lucentis still selling more than Eylea by value but is

Medius Deal Watch table for February 2015

Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology